Full Generic Medicine Info
Dosage/Direction for Use

As a mucolytic
Adult: As adjunctive therapy in respiratory tract disorders characterised by excessive, viscous mucus secretions (including COPD): Initially, 2,250 mg daily in divided doses, may be decreased to 1,500 mg daily in divided doses when a satisfactory response is obtained.
Child: 2-5 years Usual dose: 62.5-125 mg 4 times daily or 200 mg daily in 2 divided doses; 6-12 years Usual dose: 100 mg or 250 mg tid. Dosage recommendations may vary among individual products and between countries (refer to detailed product guidelines).
Should be taken with food.
Active peptic or duodenal ulcer. Children <2 years.
Special Precautions
Patient with history of gastroduodenal ulcers, chronic bronchial asthma, respiratory failure. Patients taking concomitant medicines known to cause gastrointestinal bleeding. Not recommended to be concomitantly used with antitussives and/or medicines that dry up bronchial secretions. Children (≥2 years) and elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Gastrointestinal bleeding. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, epigastric discomfort. Immune system disorders: Anaphylactic reactions, fixed drug eruption. Skin and subcutaneous tissue disorders: Rash. Rarely, bullous dermatitis (e.g. Stevens-Johnson syndrome, erythema multiforme).
Symptoms: Gastrointestinal disturbances such as gastralgia, nausea, and vomiting. Management: Supportive treatment. May perform gastric lavage, then closely observe the patient.
Carbocisteine is a mucolytic agent. The mucoregulatory mechanism of carbocisteine is not completely understood. It has been shown to reduce goblet cell hyperplasia, therefore plays a role in the management of disorders characterised by abnormal mucus.
Absorption: Rapidly and well absorbed from the gastrointestinal tract. Bioavailability: <10%. Time to peak plasma concentration: Approx 2 hours (range: 1-3 hours).
Distribution: Penetrates into the lung tissue and respiratory mucus. Volume of distribution: Approx 60-105 L.
Metabolism: Metabolised via acetylation, decarboxylation, and sulfoxidation.
Excretion: Via urine (as unchanged drug and metabolites). Elimination half-life: 1.87 hours (range: 1.4-2.5 hours).
Oral: Syrup/oral solution: Store below 25°C. Tab/cap: Store below 30°C.
CIMS Class
Cough & Cold Preparations
ATC Classification
R05CB03 - carbocisteine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.
Disclaimer: This information is independently developed by CIMS based on carbocisteine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in